|
(updated 11/9/12)
BREAST
SMMC 10-008: Risk Factor Analysis of Hereditary Breast and Ovarian Cancer
• Principal Investigator: Robert Reilly, DO
• Clinical Coordinator: Josephine Costalas, MS
• For additional information, email jcostalas@stmaryhealthcare.org
SMMC 10-005: NSABP B43 A phase III Clinical trial comparing Trastuzumab given concurrently with radiation therapy and radiation therapy alone for women with HER2 positive ductal carcinoma in situ resected by lumpectomy
• Principal Investigator: Robert Reilly, DO
• Clinical Coordinator: Christine Armetta, BS, MBA, CCRP
• For additional information, email researchinstitute@stmaryhealthcare.org
SMMC 11014: E2108 A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients with Metastatic Breast Cancer
• Principal Investigator: Robert Reilly, DO
• Clinical Coordinator: Christine Armetta, BS, MBA, CCRP
• For additional information, email researchinstitute@stmaryhealthcare.org
SMMC 11020: RTOG 1005 A Phase III Trial of Accelerated whole breast irradiation with hypofractionation plus concurrent boost vs, standard whole breast irradiation plus sequential boost for early-stage breast cancer
• Principal Investigator: Todd Flannery, MD
• Clinical Coordinator: Christine Armetta, BS, MBA, CCRP
• For additional information, email researchinstitute@stmaryhealthcare.org
SMMC 12006: E3108/SMMC12006 A phase II prospective trial correlating progression free survival with CYP2D6 activity in patients with metastatic breast cancer treated with single agent Tamoxifen
• Principal Investigator: Robert Reilly, DO
• Clinical Coordinator: Christine Armetta, BS, MBA, CCRP
• For additional information, email researchinstitute@stmaryhealthcare.org
************************************************************************
COLORECTAL
SMMC 11-007: N0949 Randomized Phase III trial of mFOLFOX7 or XELOX plus Bevacizumab vs. 5Fluorouracil/Leucovorin or Capecitabine plus bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
• Principal Investigator: Robert Reilly, DO
• Clinical Coordinator: Christine Armetta, BS, MBA, CCRP
• For additional information, email researchinstitute@stmaryhealthcare.org
************************************************************************
HEAD AND NECK/LARYNX
SMMC 11-015: R1016 Phase III trial of radiotherapy plus cetuximab vs chemoradiotherapy in HPV-associated oropharynx cancer
• Principal Investigator: Robert Reilly, DO
• Clinical Coordinator: Christine Armetta, BS, MBA, CCRP
• For additional information, email researchinstitute@stmaryhealthcare.org
SMMC 11-016: RTOG0920 A phase III study of postoperative radiation therapy (IMRT) +/- Cetuximab for locally advanced resected head and neck cancer
• Principal Investigator: Robert Reilly, DO
• Clinical Coordinator: Christine Armetta, BS, MBA, CCRP
• For additional information, email researchinstitute@stmaryhealthcare.org
************************************************************************
LUNG
SMMC 07-017: GSK1572932A Antigen-Specific Cancer
Immunotherapeutic as adjuvant therapy in patients with Non-Small Cell Lung Cancer: A double-blind, randomized, placebo-controlled Phase III study to assess the efficacy of recMAGE-A3 + AS15 Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy in patients with resectable MAGE-A3-positive Non-Small Cell Lung Cancer
• Principal Investigator: Robert Reilly, DO
• Clinical Coordinators: Jennifer Torres, RN, OCN, CCRP
• For additional information, email researchinstitute@stmaryhealthcare.org
SMMC 07-021: E1505 / A Phase III Randomized Trial of Adjuant Chemotherpay With or Without Bevacizumab for Patients With Completely Reseacted Stage IB (> 4cm) - IIIA Non-Small Cell Lung Cancer (NSCLC)
• Principal Investigator: Robert Reilly, DO
• Clinical Coordinators: Jennifer Torres, RN, OCN, CCRP
• For additional information, email researchinstitute@stmaryhealthcare.org
SMMC 10-009: IMCL CP12-0917 An open-label, multicenter, randomized, phase II study of a recombinant human anti-VEGFR-2 monoclonal antibody, IMC-1121B in combination with platinum-based chemotherapy vs. platinum based chemotherapy alone as first line treatment of patients with recurrent or advanced non-small cell lung cancer (NSCLC)
• Principal Investigator: Robert Reilly, DO
• Clinical Coordinators: Jennifer Torres, RN, OCN, CCRP
• For additional information, email researchinstitute@stmaryhealthcare.org
SMMC 10-010: E3508 A Phase II Randomized Trial of Paclitaxel, Carboplatin, Bevacizumab with or without IMC-A12 in Patients with Advanced Non-Squamous, Non-Small Cell Lung Cancer
• Principal Investigator: Robert Reilly, DO
• Clinical Coordinators: Jennifer Torres, RN, OCN, CCRP
• For additional information, email researchinstitute@stmaryhealthcare.org
SMMC-11024: PrECOG 0502/MO22097 (AvaALL) An Open-Label, Randomized, Phase IIIb Trial Evaluating The Efficacy And Safety Of Standard of Care +/- Continuous Bevacizumab Treatment Beyond Progression Of Disease In Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) After First-Line Treatment With Bevacizumab Plus A Platinum Doublet-Containing Chemotherapy
• Principal Investigator: Robert Reilly, DO
• Clinical Coordinators: Jennifer Torres, RN, OCN, CCRP
• For additional information, email researchinstitute@stmaryhealthcare.org
SMMC-12004: NSABP B47/SMMC12004 A randomized phase III trial of adjuvant therapy comparing chemotherapy alone (six cycles of Docetaxel plus Cyclophosphamide or four cycles of Doxorubicin plus cyclophosphamide followed by weekly Paclitaxel) to chemotherapy plus Trastuzumab in women with node positive or high risk node-negative HER2-Low invasive breast cancer
• Principal Investigator: Robert Reilly, DO
• Clinical Coordinators: Jennifer Torres, RN, OCN, CCRP
• For additional information, email researchinstitute@stmaryhealthcare.org
SMMC-12008: BMS 209-017/SMMC12008 An Open-label Randomized Phase III Trial of BMS-936558 versus Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC)
• Principal Investigator: Robert Reilly, DO
• Clinical Coordinators: Jennifer Torres, RN, OCN, CCRP
• For additional information, email researchinstitute@stmaryhealthcare.org
SMMC-12009: BMS CA209-057 An open-label randomized phase III trial of BMS-936558 vs. Docetaxel in previously treated metastatic non-squamous Non-small cell lung cancer (NSCLC)
• Principal Investigator: Robert Reilly, DO
• Clinical Coordinators: Jennifer Torres, RN, OCN, CCRP
• For additional information, email researchinstitute@stmaryhealthcare.org
************************************************************************
OVARIAN
SMMC 10-008: Risk Factor Analysis of Hereditary Breast and Ovarian Cancer
• Principal Investigator: Robert Reilly, DO
• Clinical Coordinator: Josephine Costalas, MS
• For additional information, email researchinstitute@stmaryhealthcare.org
************************************************************************
PANCREATIC
SMMC 09-007: Abraxis CA046 A randomized phase III study of weekly ABI-007 plus Gemcitabine vs. Gemcitabine alone in patients with metastatic adenocarcinoma of the Pancreas
• Principal Investigator: Robert Reilly, DO
• Clinical Coordinators: Jennifer Torres, RN, OCN, CCRP
• For additional information, email researchinstitute@stmaryhealthcare.org
************************************************************************
PROSTATE
SMMC 09-016: RTOG 0815/SMMC 09016 A phase III prospective randomized trial of dose-escalated radiotherapy with or without short-term androgen deprivation therapy for patients with intermediate-risk prostate cancer
• Principal Investigator: Robert Reilly, DO
• Clinical Coordinators: Jennifer Torres, RN, OCN
• For additional information, email researchinstitute@stmaryhealthcare.org
SMMC 08-014: RTOG 0534 A Phase III trial of short term androgen deprivation with pelvic lymph node or prostate bed only radiotherapy (SPORT) in prostate cancer patients with a rising PSA after radical prostatectomy
• Principal Investigator: Robert Reilly, DO
• Clinical Coordinators: Jennifer Torres, RN, OCN
• For additional information, email researchinstitute@stmaryhealthcare.org
SMMC 12003 E2809/SMMC12003 Phase II Randomized study of MK-2206 - Bicalutamide combination in patients with rising PSA at high-risk of progression after primary therapy
• Principal Investigator: Robert Reilly, DO
• Clinical Coordinator: Jennifer Torres, RN, OCN
• For additional information, email researchinstitute@stmaryhealthcare.org
|
